Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial , The Lancet

Findings from the PRINCIPLE platform trial show azithromycin did not improve in median time to self-reported recovery (estimated benefit 0.94 days; 95% Bayesian credibility interval −0.56 to 2.43) in this population, when compared to usual care ± other interventions.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news